Although there are not clinical trials evaluating NQO1 modulation in ovarian cancer, two interesting clinical trials showed important results regarding the use of two compounds that can exploit the high expression of NQO1 in tumor cells compared to normal cells. This evidence concerns the gene NQO1 and neoplasm.